Cerebral Cavernous Malformation Program

About BioAxone Biosciences

BioAxone BioSciences is a private, clinical-stage biotech company pioneering treatments for severe neurological conditions, specifically spinal cord injury and cerebral cavernous malformation. The company's technology platform centers on modulating the Rho signaling pathway, a key regulator of neuronal repair and blood-brain barrier integrity. Led by a seasoned management team with strong academic and industry backgrounds, BioAxone is advancing neuroprotective and regenerative therapies in areas with no current pharmacological options. The company operates in high-need, niche markets with potential for significant impact and premium pricing.

Therapeutic Areas

Other Cerebral Cavernous Malformation (CCM) Drugs